Trigeminal Neuralgia - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 48 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Trigeminal Neuralgia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Trigeminal Neuralgia - Pipeline Review, H2 2014', provides an overview of the Trigeminal Neuralgia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Trigeminal Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Trigeminal Neuralgia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Trigeminal Neuralgia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Trigeminal Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Trigeminal Neuralgia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Trigeminal Neuralgia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Trigeminal Neuralgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Trigeminal Neuralgia Overview 6
Therapeutics Development 7
Pipeline Products for Trigeminal Neuralgia - Overview 7
Pipeline Products for Trigeminal Neuralgia - Comparative Analysis 8
Trigeminal Neuralgia - Therapeutics under Development by Companies 9
Trigeminal Neuralgia - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Trigeminal Neuralgia - Products under Development by Companies 13
Trigeminal Neuralgia - Companies Involved in Therapeutics Development 14
Allergan, Inc. 14
Convergence Pharmaceuticals Ltd. 15
Merz Pharma GmbH & Co. KgaA 16
Trigemina, Inc. 17
Trigeminal Neuralgia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
(naltrexone + clonidine) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CNV-1014802 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
incobotulinumtoxin A - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
onabotulinumtoxin A - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
oxytocin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Trigeminal Neuralgia - Recent Pipeline Updates 36
Trigeminal Neuralgia - Product Development Milestones 43
Featured News & Press Releases 43
Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy 43
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 43
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802 44
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study 45
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802 45
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Number of Products under Development for Trigeminal Neuralgia, H2 2014 7
Number of Products under Development for Trigeminal Neuralgia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Comparative Analysis by Unknown Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Trigeminal Neuralgia - Pipeline by Allergan, Inc., H2 2014 14
Trigeminal Neuralgia - Pipeline by Convergence Pharmaceuticals Ltd., H2 2014 15
Trigeminal Neuralgia - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2014 16
Trigeminal Neuralgia - Pipeline by Trigemina, Inc., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Assessment by Combination Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Trigeminal Neuralgia Therapeutics - Recent Pipeline Updates, H2 2014 36